Almirall Overview
- Year Founded
-
1943
- Status
-
Public
- Employees
-
1,952
- Stock Symbol
-
ALM
- Investments
-
16
- Share Price
-
$9.54
- (As of Friday Closing)
Almirall General Information
Description
Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company's operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.
Contact Information
Website
www.almirall.comCorporate Office
- Ronda General Mitre, 151
- 08022 Barcelona
- Spain
Corporate Office
- Ronda General Mitre, 151
- 08022 Barcelona
- Spain
Almirall Timeline
Almirall Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.54 | $9.43 | $8.54 - $10.77 | $2.01B | 213M | 117K | -$0.21 |
Almirall Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 2,187,594 | 1,897,294 | 1,922,066 | 2,546,890 |
| Revenue | 1,001,497 | 967,934 | 907,622 | 977,992 |
| EBITDA | 124,044 | 117,674 | 164,410 | 145,814 |
| Net Income | (37,974) | (41,632) | 4,501 | (48,308) |
| Total Assets | 2,488,301 | 2,625,308 | 2,303,179 | 2,424,927 |
| Total Debt | 438,041 | 445,748 | 433,116 | 448,478 |
Almirall Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Almirall Comparisons
Industry
Financing
Details
00000
000000
Almirall Competitors (19)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | Corporation | London, United Kingdom | 0000 | 00000 | 000000000 | 00000 |
| Fortress Biotech | Formerly VC-backed | Bay Harbor Islands, FL | 000 | 00000 | 000000000 00 | 00000 |
| GSK | Corporation | Middlesex, United Kingdom | 00000 | 00.000 | 000000000 | 00.000 |
| Cipla | Corporation | Mumbai, India | 00000 | 000000&0 | ||
| Novartis | Corporation | Basel, Switzerland | 00000 | 00.00 | 000000000 | 00.00 |
Almirall Patents
Almirall Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4206196-A1 | Pyrimidine substituted derivatives as tyk2 inhibitors | Inactive | 29-Dec-2021 | 0000000000 | 0 |
| EP-4346862-A1 | Pharmaceutical composition comprising a centella asiatica extract | Pending | 26-May-2021 | 000000000 | |
| EP-4014964-A1 | Topical formulation | Inactive | 21-Dec-2020 | 0000000000 | 0 |
| JP-2023545788-A | Treatment of autoimmune diseases with dihydroorotate dehydrogenase (dhodh) inhibitors | Pending | 15-Oct-2020 | 0000000000 | |
| US-20230390276-A1 | Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor | Pending | 15-Oct-2020 | A61K31/455 |
Almirall Executive Team (35)
| Name | Title | Board Seat |
|---|---|---|
| Isabel Gomes | Chief Legal Officer & General Counsel | |
| Mercedes Diz | Chief Marketing Officer | |
| Esteve Panicot | Chief People Officer & Chief Culture Officer | |
| Karl Ziegelbauer | Chief Scientific Officer | |
| Pablo Divasson del Fraile | Senior Director of Investor Relations, Shareholders and ESG. Corporate Spokesman |
Almirall Board Members (15)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000000 0000000 | Self | Board Member | 000 0000 |
| 0000000 0000000000 | Self | Board Member | 000 0000 |
| 0000000 00 00000 0 | Self | Coordinating Independent Director | 000 0000 |
| 000-00000 00000 | Self | Board Member | 000 0000 |
| 00000 000000000 00 | Self | Board Member | 000 0000 |
Almirall Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Almirall Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Almirall Investments & Acquisitions (16)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Eloxx Pharmaceuticals (ZKN-013) | 13-Mar-2024 | 000000000 | 000 | Buildings and Property | 0000 0000 |
| DFT El Globo (Physiorelax) | 03-Feb-2023 | 000000000 | Buildings and Property | ||
| Bioniz Therapeutics | 25-Jan-2020 | 0000000000 | 0000 | Drug Delivery | 0000000 0 |
| Allergan (five dermatology brands) | 21-Sep-2018 | 000000000 | 00000 | Buildings and Property | 00000 000 |
| ThermiGen | 09-Feb-2016 | Merger/Acquisition | 0000 | Therapeutic Devices | 00000 000 |
Almirall Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Almirall Digital Garden | Accelerator/Incubator | Barcelona, Spain | 0000 |
Almirall ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
16.29 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Pharmaceuticals
Subindustry
0. of 446
Rank
Percentile
Almirall Exits (6)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Bioniz Therapeutics | 25-Jan-2020 | 000000000000 | 0000 | Completed |
|
| ThermiGen | 09-Feb-2016 | 000000000000 | 0000 | Completed |
|
| ThermiGen | 01-Sep-2015 | 00000 00000 | 000 | Completed |
|
| AB-Biotics | 19-Dec-2012 | 0000 | 00.000 | Completed |
|
| Prasfarma | 07-Mar-2001 | Secondary Transaction - Private | 000.00 | Completed |
Almirall FAQs
-
When was Almirall founded?
Almirall was founded in 1943.
-
Who is the CEO of Almirall?
Carlos Gallardo is the CEO of Almirall.
-
Where is Almirall headquartered?
Almirall is headquartered in Barcelona, Spain.
-
What is the size of Almirall?
Almirall has 1,952 total employees.
-
What industry is Almirall in?
Almirall’s primary industry is Pharmaceuticals.
-
Is Almirall a private or public company?
Almirall is a Public company.
-
What is Almirall’s stock symbol?
The ticker symbol for Almirall is ALM.
-
What is the current stock price of Almirall?
As of 13-Sep-2024 the stock price of Almirall is $9.54.
-
What is the current market cap of Almirall?
The current market capitalization of Almirall is $2.01B.
-
What is Almirall’s current revenue?
The trailing twelve month revenue for Almirall is $1B.
-
Who are Almirall’s competitors?
Hikma Pharmaceuticals, Fortress Biotech, GSK, Cipla, and Novartis are some of the 19 competitors of Almirall.
-
What is Almirall’s annual earnings per share (EPS)?
Almirall’s EPS for 12 months was -$0.21.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
